scholarly journals Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac, Sinovac) And ChAdOx1 nCoV-19 (Vaxzevria, Oxford-AstraZeneca) Vaccinations in Thai Health Care Workers

2021 ◽  
Author(s):  
Watsamon Jantarabenjakul ◽  
Napaporn Chantasrisawad ◽  
Thanyawee Puthanakit ◽  
Supaporn Wacharapluesadee ◽  
Nattiya Hirankarn ◽  
...  
Keyword(s):  
Health Care ◽  
Immune Response ◽  
Health Care Workers ◽  
Seroconversion Rate ◽  
Rapid Decline ◽  
Short Term ◽  
Rapid Reduction ◽  
Viral Neutralization ◽  
Care Workers ◽  
Vaccine Booster

Background: Inactivated SARS-CoV-2 (CoronaVac,Sinovac, or SV) and ChAdOx1 nCoV-19 (Vaxzevria,Oxford-Astra Zeneca, or AZ) vaccines have been administered to the health care workers (HCWs) in Thailand. Objective: To determine the short-term immune response after the SV and AZ vaccinations in HCWs. Methods: In this prospective cohort study, HCWs who completed a 2-dose regimen of the SV or AZ were included. Immune response was evaluated by surrogate viral neutralization test (sVNT) and anti-SARS-CoV-2 total antibody. Blood samples were analyzed at 4 and 12 weeks after the complete SV vaccination and at 4 weeks after each dose of the AZ vaccination. The primary outcome was the seroconversion rate at 4-weeks after complete immunization. Results: Overall, 185 HCWs with a median (IQR) age of 40.5(30.3-55.8) years (94 HCWs in the SV group and 91 in the AZ group) were included. At 4 weeks after completing the SV vaccination, 60.6% (95%CI:50.0-70.6%) had seroconversion evaluated by sVNT(≥68%inhibition), comparable to the patients recovered from mild COVID-19 infection(69.0%), with a rapid reduction to 12.2%(95%CI:6.3-20.8) at 12 weeks. In contrast, 85.7%(95%CI:76.8-92.2%) HCWs who completed the second dose of the AZ for 4 weeks had seroconversion, comparable to the COVID-19 pneumonia patients(92.5%). When using the anti-SAR-CoV-2 total antibody level(≥132 U/ml) criteria, only 71.3% HCWs in the SV group had seroconversion, compared to 100% in the AZ group. Conclusion: A rapid decline of short-term immune response in the HCWs after the SV vaccination indicates the need for a vaccine booster, particularly during the ongoing spreading of the SAR-CoV-2 variants of concern.

scholarly journals Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study

2020 ◽  
Vol 130 ◽  
pp. 104575 ◽  
Author(s):  
Sara Fill Malfertheiner ◽  
Susanne Brandstetter ◽  
Samra Roth ◽  
Susanne Harner ◽  
Heike Buntrock-Döpke ◽  
...  
Keyword(s):  
Health Care ◽  
Immune Response ◽  
Longitudinal Study ◽  
Health Care Workers ◽  
Prospective Longitudinal Study ◽  
Care Workers ◽  
Prospective Longitudinal

scholarly journals Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China

2020 ◽  
Vol 71 (15) ◽  
pp. 748-755 ◽  
Author(s):  
Jianlei Cao ◽  
Wen-Jun Tu ◽  
Wenlin Cheng ◽  
Lei Yu ◽  
Ya-Kun Liu ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Workers ◽  
Hospital Setting ◽  
Ground Glass Opacity ◽  
Patient Characteristics ◽  
Study Cohort ◽  
Short Term ◽  
Systemic Complications ◽  
Familial Cluster ◽  
Care Workers

Abstract Background In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China. In this study, we investigate the clinical and laboratory features and short-term outcomes of patients with coronavirus disease 2019 (COVID-19). Methods All patients with COVID-19 admitted to Wuhan University Zhongnan Hospital in Wuhan, China, between 3 January and 1 February 2020 were included. All those patients were with laboratory-confirmed infections. Epidemiological, clinical, and radiological characteristics; underlying diseases; laboratory tests; treatments; complications; and outcomes data were collected. Outcomes were followed up at discharge until 15 February 2020. Results The study cohort included 102 adult patients. The median age was 54 years (interquartile ranger, 37–67 years), and 48.0% were female. A total of 34 patients (33.3%) were exposed to a source of transmission in the hospital setting (as health-care workers, patients, or visitors) and 10 patients (9.8%) had a familial cluster. There were 18 patients (17.6%) who were admitted to the intensive care unit (ICU), and 17 patients died (mortality, 16.7%; 95% confidence interval, 9.4–23.9%). Those patients who survived were younger, were more likely to be health-care workers, and were less likely to suffer from comorbidities. They were also less likely to suffer from complications. There was no difference in drug treatment rates between the survival and nonsurvival groups. Those patients who survived were less likely to require admission to the ICU (14.1% vs 35.3% of those admitted). Chest imaging examinations showed that patients who died were more likely to have ground-glass opacity (41.2% vs 12.9% in survivors). Conclusions The mortality rate was high among the COVID-19 patients described in our cohort who met our criteria for inclusion in this analysis. The patient characteristics seen more frequently in those who died were the development of systemic complications following onset of the illness and a severity of disease requiring admission to the ICU. Our data support those described by others indicating that COVID-19 infection results from human-to-human transmission, including familial clustering of cases, and from nosocomial transmission. There were no differences in mortality among those who did or did not receive antimicrobial or glucocorticoid drug treatments.

Sign in / Sign up

Export Citation Format

Share Document